vs
Side-by-side financial comparison of WARRIOR MET COAL, INC. (HCC) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $458.6M, roughly 1.5× WARRIOR MET COAL, INC.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 15.8%, a 3.3% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs 32.0%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 7.5%).
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
HCC vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $458.6M | $708.5M |
| Net Profit | $72.3M | $135.1M |
| Gross Margin | 36.7% | — |
| Operating Margin | 17.3% | 21.6% |
| Net Margin | 15.8% | 19.1% |
| Revenue YoY | 52.1% | 32.0% |
| Net Profit YoY | — | 15.5% |
| EPS (diluted) | $1.37 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $458.6M | — | ||
| Q4 25 | $384.0M | $708.5M | ||
| Q3 25 | $328.6M | $659.9M | ||
| Q2 25 | $297.5M | $603.3M | ||
| Q1 25 | $299.9M | $558.6M | ||
| Q4 24 | $297.5M | $536.6M | ||
| Q3 24 | $327.7M | $533.3M | ||
| Q2 24 | $396.5M | $528.1M |
| Q1 26 | $72.3M | — | ||
| Q4 25 | $23.0M | $135.1M | ||
| Q3 25 | $36.6M | $111.1M | ||
| Q2 25 | $5.6M | $90.3M | ||
| Q1 25 | $-8.2M | $114.6M | ||
| Q4 24 | $1.1M | $117.0M | ||
| Q3 24 | $41.8M | $96.4M | ||
| Q2 24 | $70.7M | $88.4M |
| Q1 26 | 36.7% | — | ||
| Q4 25 | 29.5% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 23.9% | — | ||
| Q1 25 | 18.1% | — | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 29.3% | — | ||
| Q2 24 | 34.1% | — |
| Q1 26 | 17.3% | — | ||
| Q4 25 | 9.0% | 21.6% | ||
| Q3 25 | 6.3% | 21.5% | ||
| Q2 25 | 2.6% | 20.9% | ||
| Q1 25 | -5.8% | 20.3% | ||
| Q4 24 | -1.4% | 23.4% | ||
| Q3 24 | 11.9% | 21.1% | ||
| Q2 24 | 17.9% | 19.9% |
| Q1 26 | 15.8% | — | ||
| Q4 25 | 6.0% | 19.1% | ||
| Q3 25 | 11.1% | 16.8% | ||
| Q2 25 | 1.9% | 15.0% | ||
| Q1 25 | -2.7% | 20.5% | ||
| Q4 24 | 0.4% | 21.8% | ||
| Q3 24 | 12.7% | 18.1% | ||
| Q2 24 | 17.8% | 16.7% |
| Q1 26 | $1.37 | — | ||
| Q4 25 | $0.43 | $4.65 | ||
| Q3 25 | $0.70 | $3.86 | ||
| Q2 25 | $0.11 | $3.10 | ||
| Q1 25 | $-0.16 | $3.67 | ||
| Q4 24 | $0.02 | $3.67 | ||
| Q3 24 | $0.80 | $3.01 | ||
| Q2 24 | $1.35 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $233.2M | $497.0M |
| Total DebtLower is stronger | $154.4M | — |
| Stockholders' EquityBook value | — | $459.1M |
| Total Assets | $2.8B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $233.2M | — | ||
| Q4 25 | $300.0M | $497.0M | ||
| Q3 25 | $336.3M | $285.4M | ||
| Q2 25 | $383.3M | $46.3M | ||
| Q1 25 | $454.9M | $441.4M | ||
| Q4 24 | $491.5M | $669.4M | ||
| Q3 24 | $583.2M | $656.9M | ||
| Q2 24 | $709.0M | $510.9M |
| Q1 26 | $154.4M | — | ||
| Q4 25 | $154.3M | — | ||
| Q3 25 | $154.1M | — | ||
| Q2 25 | $153.9M | — | ||
| Q1 25 | $153.8M | — | ||
| Q4 24 | $153.6M | — | ||
| Q3 24 | $153.5M | — | ||
| Q2 24 | $153.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | $459.1M | ||
| Q3 25 | $2.1B | $293.6M | ||
| Q2 25 | $2.1B | $172.4M | ||
| Q1 25 | $2.1B | $593.6M | ||
| Q4 24 | $2.1B | $825.5M | ||
| Q3 24 | $2.1B | $881.4M | ||
| Q2 24 | $2.0B | $763.6M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.0B | ||
| Q3 25 | $2.7B | $1.8B | ||
| Q2 25 | $2.6B | $1.6B | ||
| Q1 25 | $2.6B | $1.9B | ||
| Q4 24 | $2.6B | $2.1B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.6B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.07× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.07× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $76.1M | $192.7M | ||
| Q3 25 | $104.7M | $246.2M | ||
| Q2 25 | $37.5M | $148.5M | ||
| Q1 25 | $10.9M | $125.8M | ||
| Q4 24 | $54.2M | $190.7M | ||
| Q3 24 | $62.2M | $149.1M | ||
| Q2 24 | $147.0M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.31× | 1.43× | ||
| Q3 25 | 2.86× | 2.22× | ||
| Q2 25 | 6.70× | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | 47.68× | 1.63× | ||
| Q3 24 | 1.49× | 1.55× | ||
| Q2 24 | 2.08× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
